Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

(NASDAQ:ARGX – Get Free Report) was upgraded by investment analysts at Sanford C. Bernstein from a “market perform” rating to ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic ...

The patients are part of Cabaletta’s RESET program across inflammatory muscle condition myositis ... generalized myasthenia gravis, multiple sclerosis and pemphigus vulgaris (PV) across 50 ...

Myasthenia gravis is a big market ... but it wasn’t until argenx progressed into Phase III with their own FcRn and myositis that investors started coming to me and saying, Hey, did you realize ...

Other Immune-Mediated Adverse Reactions The following clinically significant immune-mediated adverse reactions occurred at an incidence of less than 1% each in 1972 patients who received TEVIMBRA: ...

Cardiac/Vascular: Vasculitis. Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome ...

myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis ...

Overlap syndromes involving myasthenia gravis, myositis and myocarditis are recognised adverse effects of immune checkpoint inhibitors (ICI). We report a similar syndrome of myasthenia gravis and ...